Literature DB >> 12426412

Clinical features and comorbidity of mood fluctuations in Parkinson's disease.

Brad A Racette1, Johanna M Hartlein, Tamara Hershey, Jonathan W Mink, Joel S Perlmutter, Kevin J Black.   

Abstract

Parkinson's disease (PD) patients commonly develop fluctuations in their motor responses to levodopa within several years of initiation of treatment; some also develop nonmotor fluctuations. The authors performed a case-control study comparing the frequency of comorbid symptoms in 70 PD patients who experienced clinically apparent mood changes during their motor "on" or "off" states with two control groups with no mood fluctuations. Mood fluctuators had significantly younger age at onset and longer disease duration and were significantly more likely to have dementia, psychosis, clinical depression, and motor complications. This association remained after removing effects of age and disease duration.

Entities:  

Mesh:

Year:  2002        PMID: 12426412     DOI: 10.1176/jnp.14.4.438

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  10 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 3.  Anxiety in Parkinson's disease: identification and management.

Authors:  Jack J Chen; Laura Marsh
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

4.  Anxiety and self-perceived health status in Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne R Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Parkinsonism Relat Disord       Date:  2011-02-02       Impact factor: 4.891

5.  Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.

Authors:  Paolo Barone; Leonardo Scarzella; Roberto Marconi; Angelo Antonini; Letterio Morgante; Fulvio Bracco; Mario Zappia; Bruno Musch
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

Review 6.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

7.  Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality.

Authors:  Jared T Hinkle; Kate Perepezko; Zoltan Mari; Laura Marsh; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2018-01-31       Impact factor: 4.105

Review 8.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  A perfusion MRI study of emotional valence and arousal in Parkinson's disease.

Authors:  Sunsern Limsoontarakul; Meghan C Campbell; Kevin J Black
Journal:  Parkinsons Dis       Date:  2011-09-28

10.  Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in Parkinson's disease.

Authors:  Regina Rendas-Baum; Philip O Buck; Michelle K White; Jane Castelli-Haley
Journal:  Health Qual Life Outcomes       Date:  2011-08-18       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.